-
Association Between Syncope Trigger Type and Risk of Subsequent Life-Threatening Events in Patients With Long QT Syndrome. JAMA Cardiol. (IF 24.0) Pub Date : 2023-07-12 Arwa Younis,J Martijn Bos,Wojciech Zareba,Mehmet K Aktas,Arthur A M Wilde,Chadi Tabaja,Christopher Bodurian,Kathryn E Tobert,Scott McNitt,Bronislava Polonsky,Wataru Shimizu,Michael J Ackerman,Ilan Goldenberg
Importance Syncope is the most powerful predictor for subsequent life-threatening events (LTEs) in patients with congenital long QT syndrome (LQTS). Whether distinct syncope triggers are associated with differential subsequent risk of LTEs is unknown. Objective To evaluate the association between adrenergic (AD)- and nonadrenergic (non-AD)-triggered syncopal events and the risk of subsequent LTEs in
-
Serial N-Terminal Pro-B-Type Natriuretic Peptide Measurements in the Population Without Clinical Heart Failure. JAMA Cardiol. (IF 24.0) Pub Date : 2023-07-12 Zhehao Dai,Sachiko Ohde
-
A Patient in Their 70s With Bright Red Blood in the Pericardiocentesis Catheter. JAMA Cardiol. (IF 24.0) Pub Date : 2023-07-05 Tomislav Tokic,Ivan Burcar,Hrvoje Gasparovic
-
Assessment of Oxygen Pulse in Hypertrophic Cardiomyopathy. JAMA Cardiol. (IF 24.0) Pub Date : 2023-07-05 Jan Gerrit van der Stouwe,Christian M Schmied,David Niederseer
-
Novel Association of the NOTCH Pathway Regulator MIB1 Gene With the Development of Bicuspid Aortic Valve. JAMA Cardiol. (IF 24.0) Pub Date : 2023-07-05 Idit Tessler,Juliette Albuisson,Rebeca Piñeiro-Sabarís,Aline Verstraeten,Hatem Elif Kamber Kaya,Marcos Siguero-Álvarez,Guillaume Goudot,Donal MacGrogan,Ilse Luyckx,Shoshana Shpitzen,Galina Levin,Guy Kelman,Noga Reshef,Hugo Mananet,Jake Holdcraft,Jochen D Muehlschlegel,Gina M Peloso,Olya Oppenheim,Charles Cheng,Jean-Michael Mazzella,Gregor Andelfinger,Seema Mital,Per Eriksson,Clarisse Billon,Mahyar
Importance Nonsyndromic bicuspid aortic valve (nsBAV) is the most common congenital heart valve malformation. BAV has a heritable component, yet only a few causative genes have been identified; understanding BAV genetics is a key point in developing personalized medicine. Objective To identify a new gene for nsBAV. Design, Setting, and Participants This was a comprehensive, multicenter, genetic association
-
Assessment of Oxygen Pulse in Hypertrophic Cardiomyopathy-Reply. JAMA Cardiol. (IF 24.0) Pub Date : 2023-07-05 Matthew T Wheeler,Yu-Mao Chen,Jonathan Myers
-
Coronary Atherosclerotic Plaque Activity and Future Coronary Events. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-28 Alastair Moss,Marwa Daghem,Evangelos Tzolos,Mohammed N Meah,Kang-Ling Wang,Anda Bularga,Philip D Adamson,Jacek Kwiecinski,Alison Fletcher,Dana Dawson,Parthiban Arumugam,Nikant Sabharwal,John P Greenwood,Jon N Townend,Patrick A Calvert,James H F Rudd,Dan Berman,Johan Verjans,Piotr Slomka,Damini Dey,Laura Forsyth,Lauren Murdoch,Robert J Lee,Steff Lewis,Nicholas L Mills,Edwin J R van Beek,Michelle C Williams
Importance Recurrent coronary events in patients with recent myocardial infarction remain a major clinical problem. Noninvasive measures of coronary atherosclerotic disease activity have the potential to identify individuals at greatest risk. Objective To assess whether coronary atherosclerotic plaque activity as assessed by noninvasive imaging is associated with recurrent coronary events in patients
-
Gauging the Success of Low-Voltage-Area Ablation. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-28 Kristen K Patton
-
Comments on the myPACE Randomized Clinical Trial-Reply. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-28 Margaret Infeld,Daniel L Lustgarten,Markus Meyer
-
Comments on the myPACE Randomized Clinical Trial. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-28 Massimiliano Camilli,Roberto Scacciavillani,Filippo Crea
-
Management of Postpartum Left Main Spontaneous Coronary Artery Dissection. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-28 Chayakrit Krittanawong,Michael J Attubato,Lori Vales Lay
-
Comparative Effectiveness of Percutaneous Microaxial Left Ventricular Assist Device vs Intra-Aortic Balloon Pump or No Mechanical Circulatory Support in Patients With Cardiogenic Shock. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-21 Zaid I Almarzooq,Yang Song,Issa J Dahabreh,Ajar Kochar,Enrico G Ferro,Eric A Secemsky,Jacqueline M Major,Andrew Farb,Changfu Wu,Bram Zuckerman,Robert W Yeh
Importance Recent studies have produced inconsistent findings regarding the outcomes of the percutaneous microaxial left ventricular assist device (LVAD) during acute myocardial infarction with cardiogenic shock (AMICS). Objective To compare the percutaneous microaxial LVAD vs alternative treatments among patients presenting with AMICS using observational analyses of administrative data. Design, Setting
-
Woman in Her 50s With Pulmonary Hypertension Associated With Takayasu Arteritis. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-21 Kentaro Ejiri,Satoshi Akagi,Hiroshi Ito
-
What Role for New York Heart Association Class in Heart Failure Clinical Trials? JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-21 Felix Lindberg,Daniela Tomasoni,Gianluigi Savarese
-
Evidence Generation for Novel Cardiovascular Devices-Putting the Horse Back in Front of the Cart. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-21 David J Cohen,Manesh R Patel
-
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-14 Rajiv Agarwal,Bertram Pitt,Peter Rossing,Stefan D Anker,Gerasimos Filippatos,Luis M Ruilope,Csaba P Kovesdy,Katherine Tuttle,Muthiah Vaduganathan,Christoph Wanner,Sameer Bansilal,Martin Gebel,Amer Joseph,Robert Lawatscheck,George L Bakris
Importance It is currently unclear whether chronic kidney disease (CKD)-associated cardiovascular risk in type 2 diabetes (T2D) is modifiable. Objective To examine whether cardiovascular risk can be modified with finerenone in patients with T2D and CKD. Design, Setting, and Participants Incidence rates from Finerenone in Chronic Kidney Disease and Type 2 Diabetes: Combined FIDELIO-DKD and FIGARO-DKD
-
Unusual Source of Dysphagia in a Man in His Eighth Decade of Life. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-14 Shaina Ailawadi,Polsha Jules,Damian Valencia
-
Implementing Shared Decision-making for Patients With Aortic Stenosis With Longer Life Expectancy. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-14 Megan Coylewright
-
Mitigating Cardiovascular Disease Risk in Patients With Type 2 Diabetes and Chronic Kidney Disease-An Unmet Need With Promising Solutions. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-14 Janani Rangaswami,Roy O Mathew
-
Diagnostic and Prognostic Value of Stress Cardiovascular Magnetic Resonance Imaging in Patients With Known or Suspected Coronary Artery Disease: A Systematic Review and Meta-analysis. JAMA Cardiol. (IF 24.0) Pub Date : 2023-07-01 Fabrizio Ricci,Mohammed Y Khanji,Giandomenico Bisaccia,Alberto Cipriani,Annamaria Di Cesare,Laura Ceriello,Cesare Mantini,Marco Zimarino,Artur Fedorowski,Sabina Gallina,Steffen E Petersen,Chiara Bucciarelli-Ducci
Importance The clinical utility of stress cardiovascular magnetic resonance imaging (CMR) in stable chest pain is still debated, and the low-risk period for adverse cardiovascular (CV) events after a negative test result is unknown. Objective To provide contemporary quantitative data synthesis of the diagnostic accuracy and prognostic value of stress CMR in stable chest pain. Data Sources PubMed and
-
Genetic Risk Factors Associated With Preeclampsia and Hypertensive Disorders of Pregnancy. JAMA Cardiol. (IF 24.0) Pub Date : 2023-07-01 Jaakko S Tyrmi,Tea Kaartokallio,A Inkeri Lokki,Tiina Jääskeläinen,Eija Kortelainen,Sanni Ruotsalainen,Juha Karjalainen,Samuli Ripatti,Anna Kivioja,Triin Laisk,Johannes Kettunen,Anneli Pouta,Katja Kivinen,Eero Kajantie,Seppo Heinonen,Juha Kere,Hannele Laivuori,
Importance A genetic contribution to preeclampsia susceptibility has been established but is still incompletely understood. Objective To disentangle the underlying genetic architecture of preeclampsia and preeclampsia or other maternal hypertension during pregnancy with a genome-wide association study (GWAS) of hypertensive disorders of pregnancy. Design, Setting, and Participants This GWAS included
-
The Case for Inclusion of a Lipid Panel in the Standard Precatheterization Laboratory Blood Draw-Stating What Should Be Obvious. JAMA Cardiol. (IF 24.0) Pub Date : 2023-07-01 Lauren S Ranard,Eamon Y Duffy,Ajay J Kirtane
-
Association of Circulating Cardiomyocyte Cell-Free DNA With Cancer Therapy-Related Cardiac Dysfunction in Patients Undergoing Treatment for ERBB2-Positive Breast Cancer. JAMA Cardiol. (IF 24.0) Pub Date : 2023-07-01 Anthony F Yu,Zachary R Moore,Chaya S Moskowitz,Jennifer E Liu,Chau T Dang,Lakshmi Ramanathan,Kevin C Oeffinger,Richard M Steingart,Adam M Schmitt
Importance Cancer therapy-related cardiac dysfunction (CTRCD) is a potentially serious cardiotoxicity of treatments for ERBB2-positive breast cancer (formerly HER2). Identifying early biomarkers of cardiotoxicity could facilitate an individualized approach to cardiac surveillance and early pharmacologic intervention. Circulating cell-free DNA (cfDNA) of cardiomyocyte origin is present during acute
-
Percutaneous Coronary Intervention vs Coronary Artery Bypass Graft Surgery for Left Main Disease in Patients With and Without Acute Coronary Syndromes: A Pooled Analysis of 4 Randomized Clinical Trials. JAMA Cardiol. (IF 24.0) Pub Date : 2023-07-01 Prakriti Gaba,Evald H Christiansen,Per H Nielsen,Sabina A Murphy,Patrick T O'Gara,Peter K Smith,Patrick W Serruys,A Pieter Kappetein,Seung-Jung Park,Duk-Woo Park,Gregg W Stone,Joseph F Sabik,Marc S Sabatine,Niels R Holm,Brian A Bergmark
Importance Patients with left main coronary artery disease presenting with an acute coronary syndrome (ACS) represent a high-risk and understudied subgroup of patients with atherosclerosis. Objective To assess clinical outcomes after PCI vs CABG in patients with left main disease with vs without ACS. Design, Setting, and Participants Data were pooled from 4 trials comparing PCI with drug-eluting stents
-
Explanation of Error in the Clinical Challenge, "A Case of Right Bundle Branch Block With Changing Axis". JAMA Cardiol. (IF 24.0) Pub Date : 2023-07-01 Robert B King,Ramil Goel
-
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial. JAMA Cardiol. (IF 24.0) Pub Date : 2023-07-01 Javed Butler,Muhammad Shariq Usman,Gerasimos Filippatos,João Pedro Ferreira,Michael Böhm,Martina Brueckmann,James L Januzzi,Sanjay Kaul,Ileana L Piña,Piotr Ponikowski,Michele Senni,Mikhail Sumin,Subodh Verma,Liliana Zaremba-Pechmann,Stuart J Pocock,Milton Packer,Stefan Anker
Importance The diuretic effect of sodium-glucose cotransporter 2 inhibitors may result in interaction with background diuretic therapy in patients with heart failure and preserved ejection fraction (HFpEF). Objective To assess the safety and efficacy of empagliflozin in combination with background diuretic therapy and the association of empagliflozin with the need for conventional diuretics. Design
-
Cardiovascular Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure-Does the Story Begin and End With the Kidney? JAMA Cardiol. (IF 24.0) Pub Date : 2023-07-01 Ravi B Patel
-
When Is a High Lipoprotein (a) Concentration Too High?-The Need for Diverse Population-Based Samples. JAMA Cardiol. (IF 24.0) Pub Date : 2023-07-01 Sadiya S Khan
-
Heterogeneity of Lipoprotein(a) Levels Among Hispanic or Latino Individuals Residing in the US. JAMA Cardiol. (IF 24.0) Pub Date : 2023-07-01 Parag H Joshi,Santica Marcovina,Kate Orroth,J Antonio G López,Shia T Kent,Robert Kaplan,Katrina Swett,Daniela Sotres-Alvarez,Bharat Thyagarajan,Leandro Slipczuk,Tamar Sofer,Martha L Daviglus,Gregory A Talavera,Neil Schneiderman,Carlos J Rodriguez
Importance Lipoprotein(a) (Lp[a]) is a genetically determined risk-enhancing factor for atherosclerotic cardiovascular disease (ASCVD). The Lp(a) distribution among the diverse Hispanic or Latino community residing in the US has not been previously described, to the authors' knowledge. Objective To determine the distribution of Lp(a) levels across a large cohort of diverse Hispanic or Latino adults
-
Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry. JAMA Cardiol. (IF 24.0) Pub Date : 2023-07-01 Jacob B Pierce,Muthiah Vaduganathan,Gregg C Fonarow,Uchechukwu Ikeaba,Karen Chiswell,Javed Butler,Adam D DeVore,Paul A Heidenreich,Joanna C Huang,Michelle M Kittleson,Karen E Joynt Maddox,Karthik K Linganathan,James J McDermott,Anjali Tiku Owens,Pamela N Peterson,Scott D Solomon,Orly Vardeny,Clyde W Yancy,Stephen J Greene
Importance Clinical guidelines for patients with heart failure with reduced ejection fraction (HFrEF) strongly recommend treatment with a sodium-glucose cotransporter-2 inhibitor (SGLT2i) to reduce cardiovascular mortality or HF hospitalization. Nationwide adoption of SGLT2i for HFrEF in the US is unknown. Objective To characterize patterns of SGLT2i use among eligible US patients hospitalized for
-
Age Dependency of Cardiovascular Outcomes With the Amyloidogenic pV142I Transthyretin Variant Among Black Individuals in the US. JAMA Cardiol. (IF 24.0) Pub Date : 2023-05-22 Senthil Selvaraj,Brian L Claggett,C Cristina Quarta,Bing Yu,Riccardo M Inciardi,Joel N Buxbaum,Thomas H Mosley,Amil M Shah,Sharmila Dorbala,Rodney H Falk,Scott D Solomon
Importance Hereditary transthyretin cardiac amyloidosis is an increasingly recognized cause of heart failure (HF) with distinct treatment. The amyloidogenic pV142I (V122I) variant is present in 3% to 4% of Black individuals in the US and increases the risk for atrial fibrillation (AF), HF, and mortality. Since hereditary transthyretin cardiac amyloidosis demonstrates age-dependent anatomic penetrance
-
Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial. JAMA Cardiol. (IF 24.0) Pub Date : 2023-07-01 Alexander Peikert,Alvin Chandra,Mikhail N Kosiborod,Brian L Claggett,Akshay S Desai,Pardeep S Jhund,Carolyn S P Lam,Silvio E Inzucchi,Felipe A Martinez,Rudolf A de Boer,Adrian F Hernandez,Sanjiv J Shah,Stefan P Janssens,Jan Belohlávek,C Jan Willem Borleffs,Dan Dobreanu,Anna Maria Langkilde,Olof Bengtsson,Magnus Petersson,John J V McMurray,Scott D Solomon,Muthiah Vaduganathan
Importance Dapagliflozin has been shown to improve overall health status based on aggregate summary scores of the Kansas City Cardiomyopathy Questionnaire (KCCQ) in patients with heart failure (HF) with mildly reduced or preserved ejection fraction enrolled in the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial. A comprehensive
-
Titanium-Nitride-Oxide-Coated vs Everolimus-Eluting Stents in Acute Coronary Syndrome: 5-Year Clinical Outcomes of the TIDES-ACS Randomized Clinical Trial. JAMA Cardiol. (IF 24.0) Pub Date : 2023-07-01 Frederic Bouisset,Jussi Sia,Takuya Mizukami,Pasi P Karjalainen,Pim A L Tonino,Nico H J Pijls,Jan Van der Heyden,Hannu Romppanen,Kari Kervinen,Juhani K E Airaksinen,Jacques Lalmand,Peter Frambach,Bruno Roza da Costa,Carlos Collet,Bernard De Bruyne,
Importance Titanium-nitride-oxide (TiNO)-coated stents show faster strut coverage compared with drug-eluting stents without excessive intimal-hyperplasia observed in bare metal stents. It is important to study long-term clinical outcomes after treatment of patients with an acute coronary syndrome (ACS) by TiNO-coated stents, which are neither drug-eluting stents nor bare metal stents. Objective To
-
Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-01 Rachel Lampert,Michael J Ackerman,Bradley S Marino,Matthew Burg,Barbara Ainsworth,Lisa Salberg,Maria Teresa Tome Esteban,Carolyn Y Ho,Roselle Abraham,Seshadri Balaji,Cheryl Barth,Charles I Berul,Martijn Bos,David Cannom,Lubna Choudhury,Maryann Concannon,Robert Cooper,Richard J Czosek,Anne M Dubin,James Dziura,Benjamin Eidem,Michael S Emery,N A Mark Estes,Susan P Etheridge,Jeffrey B Geske,Belinda Gray
Importance Whether vigorous intensity exercise is associated with an increase in risk of ventricular arrhythmias in individuals with hypertrophic cardiomyopathy (HCM) is unknown. Objective To determine whether engagement in vigorous exercise is associated with increased risk for ventricular arrhythmias and/or mortality in individuals with HCM. The a priori hypothesis was that participants engaging
-
A Woman With Syncope and Frequent Premature Ventricular Contractions. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-01 Mazen M Kawji
-
Skeletal Muscle Mitochondrial Respiration and Exercise Intolerance in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-01 Lina Scandalis,Dalane W Kitzman,Barbara J Nicklas,Mary Lyles,Peter Brubaker,M Benjamin Nelson,Michelle Gordon,John Stone,Jaclyn Bergstrom,P Darrell Neufer,Erich Gnaiger,Anthony J A Molina
Importance The pathophysiology of exercise intolerance in patients with heart failure with preserved ejection fraction (HFpEF) remains incompletely understood. Multiple lines of evidence suggest that abnormal skeletal muscle metabolism is a key contributor, but the mechanisms underlying metabolic dysfunction remain unresolved. Objective To evaluate the associations of skeletal muscle mitochondrial
-
Automated Assessment of Cardiac Systolic Function From Coronary Angiograms With Video-Based Artificial Intelligence Algorithms. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-01 Robert Avram,Joshua P Barrios,Sean Abreau,Cheng Yee Goh,Zeeshan Ahmed,Kevin Chung,Derek Y So,Jeffrey E Olgin,Geoffrey H Tison
Importance Understanding left ventricular ejection fraction (LVEF) during coronary angiography can assist in disease management. Objective To develop an automated approach to predict LVEF from left coronary angiograms. Design, Setting, and Participants This was a cross-sectional study with external validation using patient data from December 12, 2012, to December 31, 2019, from the University of California
-
Skeletal Muscle Mitochondrial Dysfunction and Exercise Intolerance in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-01 Ambarish Pandey,Neil Keshvani,Windy Alonso
-
CRISPR Editing Takes Aim at Ischemia/Reperfusion Injury. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-01 Oscar E Reyes Gaido,Mark E Anderson
-
Young Man With Coarctation of the Aorta. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-01 Luis David Beltran Ontiveros,Juan Francisco Fritche Salazar,Hugo Rodriguez Zanella
-
Association Between Intensive vs Standard Blood Pressure Control and Incident Left Ventricular Conduction Disease: A Post Hoc Analysis of the SPRINT Randomized Clinical Trial. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-01 Emilie K Frimodt-Møller,Eric Vittinghoff,Gurbani Kaur,Tor Biering-Sørensen,Elsayed Z Soliman,Gregory M Marcus
Importance Left ventricular conduction disease predicts heart failure and death, and the only strategies to mitigate its effects involve implantation of a permanent pacemaker. There are currently no proven preventive strategies for this common condition. Objective To determine the association between targeting intensive blood pressure (BP) control and the risk of developing left ventricular conduction
-
Cardiovascular Disease Risk Assessment Using Traditional Risk Factors and Polygenic Risk Scores in the Million Veteran Program. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-01 Jason L Vassy,Daniel C Posner,Yuk-Lam Ho,David R Gagnon,Ashley Galloway,Vidisha Tanukonda,Serena C Houghton,Ravi K Madduri,Benjamin H McMahon,Philip S Tsao,Scott M Damrauer,Christopher J O'Donnell,Themistocles L Assimes,Juan P Casas,J Michael Gaziano,Michael J Pencina,Yan V Sun,Kelly Cho,Peter W F Wilson
Importance Primary prevention of atherosclerotic cardiovascular disease (ASCVD) relies on risk stratification. Genome-wide polygenic risk scores (PRSs) are proposed to improve ASCVD risk estimation. Objective To determine whether genome-wide PRSs for coronary artery disease (CAD) and acute ischemic stroke improve ASCVD risk estimation with traditional clinical risk factors in an ancestrally diverse
-
Efficacy and Safety of Low-Dose Triple and Quadruple Combination Pills vs Monotherapy, Usual Care, or Placebo for the Initial Management of Hypertension: A Systematic Review and Meta-analysis. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-01 Nelson Wang,Phidias Rueter,Emily Atkins,Ruth Webster,Mark Huffman,Asita de Silva,Clara Chow,Anushka Patel,Anthony Rodgers
Importance Low-dose combination (LDC) antihypertensives consisting of 3 or 4 blood pressure (BP)-lowering drugs have emerged as a potentially important therapy for the initial management of hypertension. Objective To assess the efficacy and safety of LDC therapies for the management of hypertension. Data Sources PubMed and Medline were searched from date of inception until September 2022. Study Selection
-
Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-01 Pardeep S Jhund,Brian L Claggett,Atefeh Talebi,Jawad H Butt,Samvel B Gasparyan,Lee-Jen Wei,Zachary R McCaw,Ulrica Wilderäng,Olof Bengtsson,Akshay S Desai,Magnus Petersson,Anna Maria Langkilde,Rudolf A de Boer,Adrian F Hernandez,Silvio E Inzucchi,Mikhail N Kosiborod,Carolyn S P Lam,Felipe A Martinez,Sanjiv J Shah,Muthiah Vaduganathan,Scott D Solomon,John J V McMurray
Importance In the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial, dapagliflozin reduced the risk of time to first worsening heart failure (HF) event or cardiovascular death in patients with HF with mildly reduced or preserved ejection fraction (EF). Objective To evaluate the effect of dapagliflozin on total (ie, first and recurrent)
-
A Woman With Recurrent Syncope and Malar Flush in the Setting of a Left Atrial Echogenic Mass. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-01 Zhenyu Dong,Yanmei Lu,Baopeng Tang
-
Quality of Care and Clinical Outcomes for Patients With Heart Failure at Hospitals Caring for a High Proportion of Black Adults: Get With The Guidelines-Heart Failure Registry. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-01 Jamie Diamond,Iyanuoluwa Ayodele,Gregg C Fonarow,Karen E Joynt-Maddox,Robert W Yeh,Gmerice Hammond,Larry A Allen,Stephen J Greene,Karen Chiswell,Adam D DeVore,Clyde Yancy,Rishi K Wadhera
Importance Black adults with heart failure (HF) disproportionately experience higher population-level mortality than White adults with HF. Whether quality of care for HF differs at hospitals with high proportions of Black patients compared with other hospitals is unknown. Objective To compare quality and outcomes for patients with HF at hospitals with high proportions of Black patients vs other hospitals
-
How Do We Credit the Evidence Generated From Subgroup Analyses in Randomized Clinical Trials?-Reply. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-01 Mark A Hlatky,Neil J Stone,JoAnn E Manson
-
Indication Creep in Transcatheter Aortic Valve Implantation-Data or Desire? JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-01 Sachin S Goel,Michael J Reardon
-
Comprehensive Cardiovascular Magnetic Resonance Tissue Characterization and Cardiotoxicity in Women With Breast Cancer. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-01 Paaladinesh Thavendiranathan,Tamar Shalmon,Chun-Po Steve Fan,Christian Houbois,Eitan Amir,Yobiga Thevakumaran,Emily Somerset,Julia M Malowany,Camila Urzua-Fresno,Paul Yip,Chris McIntosh,Marshall S Sussman,Christine Brezden-Masley,Andrew T Yan,C Anne Koch,Neil Spiller,Husam Abdel-Qadir,Coleen Power,Kate Hanneman,Bernd J Wintersperger
Importance There is a growing interest in understanding whether cardiovascular magnetic resonance (CMR) myocardial tissue characterization helps identify risk of cancer therapy-related cardiac dysfunction (CTRCD). Objective To describe changes in CMR tissue biomarkers during breast cancer therapy and their association with CTRCD. Design, Setting, and Participants This was a prospective, multicenter
-
Acute Respiratory Distress Following Percutaneous Coronary Intervention of Osteal Occlusion of Left Main Coronary Artery. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-01 Mochamad Yusuf Alsagaff,Makyhan Jibril Al Farabi,Arief Bakhtiar
-
Aspirin vs Clopidogrel for Long-term Maintenance After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the HOST-EXAM Trial. JAMA Cardiol. (IF 24.0) Pub Date : 2023-06-01 Tae-Min Rhee,Jang-Whan Bae,Kyung Woo Park,Seung-Woon Rha,Jeehoon Kang,Heesun Lee,Han-Mo Yang,Soo-Heon Kwak,In-Ho Chae,Won-Yong Shin,Dae-Kyeong Kim,Ju Hyeon Oh,Myung Ho Jeong,Yong Hoon Kim,Nam Ho Lee,Seung-Ho Hur,Junghan Yoon,Jung-Kyu Han,Eun-Seok Shin,Bon-Kwon Koo,Hyo-Soo Kim,
Importance Selecting the optimal antiplatelet agent in patients who have received percutaneous coronary intervention is especially important in those with diabetes due to the heightened risk of ischemic events in this population. Studies on the efficacy and safety of clopidogrel vs aspirin for long-term maintenance after percutaneous coronary intervention in patients with diabetes are lacking. Objective
-
A 65-Year-Old Woman With Dyspnea and Recurrent Abdominal Distension. JAMA Cardiol. (IF 24.0) Pub Date : 2023-05-01 Joseph M Kim,Bradley A Maron
-
Worsening Dyspnea and New-Onset Atrial Fibrillation in a 79-Year-Old Woman. JAMA Cardiol. (IF 24.0) Pub Date : 2023-05-01 Christopher C Cheung,Edward P Gerstenfeld
-
Association of the Timing and Extent of Cardiac Implantable Electronic Device Infections With Mortality. JAMA Cardiol. (IF 24.0) Pub Date : 2023-05-01 Hui-Chen Han,Jia Wang,David H Birnie,Marco Alings,François Philippon,Ratika Parkash,Jaimie Manlucu,Paul Angaran,Claus Rinne,Benoit Coutu,R Aaron Low,Vidal Essebag,Carlos Morillo,Jeffrey S Healey,Damian Redfearn,Satish Toal,Giuliano Becker,Michel DeGrâce,Bernard Thibault,Eugene Crystal,Stanley Tung,John LeMaitre,Omar Sultan,Matthew Bennett,Jamil Bashir,Felix Ayala-Paredes,Philippe Gervais,Leon Rioux
Importance Cardiac implantable electronic device (CIED) infection is a potentially devastating complication with an estimated 12-month mortality of 15% to 30%. The association of the extent (localized or systemic) and timing of infection with all-cause mortality has not been established. Objective To evaluate the association of the extent and timing of CIED infection with all-cause mortality. Design
-
Modeling the Association of Volume vs Composite Outcome Thresholds With Outcomes and Access to Transcatheter Aortic Valve Implantation in the US. JAMA Cardiol. (IF 24.0) Pub Date : 2023-05-01 Adam J Nelson,Zachary K Wegermann,Dianne Gallup,Sean O'Brien,Andrzej S Kosinski,Vinod H Thourani,Dharam J Kumbhani,Ajay Kirtane,Joseph Allen,John D Carroll,David M Shahian,Nimesh D Desai,Ralph G Brindis,Eric D Peterson,David J Cohen,Sreekanth Vemulapalli
Importance Professional societies and the Centers for Medicare & Medicaid Services suggest volume thresholds to ensure quality in transcatheter aortic valve implantation (TAVI). Objective To model the association of volume thresholds vs spoke-and-hub implementation of outcome thresholds with TAVI outcomes and geographic access. Design, Setting, and Participants This cohort study included patients who
-
Assessing Heart Failure vs Lymphoma Treatment Risks and Benefits-It Takes Two to Tango. JAMA Cardiol. (IF 24.0) Pub Date : 2023-05-01 Ana Barac
-
More Attention Should Be Paid to Less Severe Nonculprit Lesions-Reply. JAMA Cardiol. (IF 24.0) Pub Date : 2023-05-01 Shamir R Mehta,Natalia Pinilla-Echeverri,John A Cairns
-
More Attention Should Be Paid to Less Severe Nonculprit Lesions. JAMA Cardiol. (IF 24.0) Pub Date : 2023-05-01 Shichu Liang,Min Ma,Yong He
-
Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell Lymphoma. JAMA Cardiol. (IF 24.0) Pub Date : 2023-05-01 Jenica N Upshaw,Jason Nelson,Angie Mae Rodday,Anita J Kumar,Andreas K Klein,Marvin A Konstam,John B Wong,Iris Z Jaffe,Bonnie Ky,Jonathan W Friedberg,Matthew Maurer,David M Kent,Susan K Parsons
Importance Anthracycline-containing regimens are highly effective for diffuse large B-cell lymphoma (DLBCL); however, patients with preexisting heart failure (HF) may be less likely to receive anthracyclines and may be at higher risk of lymphoma mortality. Objective To assess the prevalence of preexisting HF in older patients with DLBCL and its association with treatment patterns and outcomes. Design
-
Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020. JAMA Cardiol. (IF 24.0) Pub Date : 2023-05-01 Joshua A Jacobs,Daniel K Addo,Alexander R Zheutlin,Catherine G Derington,Utibe R Essien,Ann Marie Navar,Inmaculada Hernandez,Donald M Lloyd-Jones,Jordan B King,Shreya Rao,Jennifer S Herrick,Adam P Bress,Ambarish Pandey
Importance The burden of atherosclerotic cardiovascular disease (ASCVD) in the US is higher among Black and Hispanic vs White adults. Inclusion of race in guidance for statin indication may lead to decreased disparities in statin use. Objective To evaluate prevalence of primary prevention statin use by race and ethnicity according to 10-year ASCVD risk. Design, Setting, and Participants This serial